


























































Abstract		In	the	past	few	years,	 interferon-induced	transmembrane	(IFITM)	proteins	have	been	identified	as	important	antiviral	factors.	The	current	understanding	of	IFITMs	suggests	that	they	localise	within	distinct	cellular	compartments	from	where	they	exert	 their	 broad	 antiviral	 role.	 For	 example,	 IFITM1	 localises	 to	 the	 plasma	membrane	and	restricts	viruses	that	do	not	require	endocytosis	to	infect	host	cells.	In	 contrast,	 IFITM2	 and	 IFITM3	 are	 found	 in	 the	 early	 and	 late	 endosomes,	respectively,	 and	 are	 potent	 inhibitors	 of	 viruses	 that	 depend	 on	 endosomal	pathways	for	infection.				I	begin	this	dissertation	by	providing	some	background	on	the	biology	and	function	of	 IFITM	proteins,	 including	details	of	 in	vitro	assays	 that	have	helped	elucidate	









































































































































































































































































T-cell	receptors	(TCR)	on	the	surface	of	T-lymphocytes.	On	the	other	hand,	the	role	of	the	innate	immune	response	involves	the	activation	of	granulocytes,	dendritic	cells	and	macrophages	and	it	is	regarded	as	relatively	unspecific(3).			Responses	of	the	innate	system	to	pathogenic	challenge	rely	on	the	recognition	of	conserved	structures	on	pathogens	which	are	commonly	referred	to	as	pathogen-associated	 molecular	 patterns	 (PAMPs)(3).	 Four	 main	 pattern	 recognition	receptors	 (PRR)	 families	 have	 been	 identified,	 the	 transmembrane	 toll-like	receptors	(TLRs),	C-type	lectin	receptors	(CLRs),	nod-like	receptors	and	retinoic	acid-inducible	gene	(RIG)-I-like	receptors	(RLRs)	(1,	4)	(See	Figure	1).	
	














C-Type	lectin	receptor	signalling		C-type	 lectin	 receptors	 are	 vital	 for	 viral	 recognition.	 CLRs	 are	 expressed	 by	antigen	presenting	cells	such	as	dendritic	cells	and	macrophages,	thereby	eliciting	a	rapid	innate	response	upon	virus	infection.	CLRs	can	be	classified	into	four	main	groups:	immunoreceptor	tyrosine-based	activating	motif	(ITAM)	CLRs,	hemi-ITAM	(hemITAM)	CLRs,	immunoreceptor	tyrosine-based	inhibitory	motif	(ITIM)-	CLRs,	and	a	group	of	CLRs	lacking	typical	signalling	motif	such	as	DC-SIGN(16).			Despite	the	C-type	lectin	role	as	antiviral	factors,	they	are	exploited	by	viruses	such	as	HIV-1	in	order	to	gain	entry	into	host	cells	and	to	inhibit	APCs	function(17).	For	example,	 upon	 DC-SIGN	 recognition	 of	 HIV,	 the	 virions	 are	 transported	 to	 the	proteasome	where	lysosomal	degradation	takes	place.	Recognition	of	HIV-1	also	triggers	Raf-1	activation	and	the	modulation	of	cytokine	responses	through	NF-kB	activation.	HIV	binding	 and	 recruitment	 of	Raf-1	dependent	 phosphorylation	 of	NF-kB	also	leads	to	the	recruitment	of	transcription	elongation	factor	pTEF-b	to	nascent	 transcripts	 leading	 to	 transcription	 elongation	 and	 generation	 of	 full-length	 viral	 transcripts(18).	 Therefore,	 although	 CLRs	 are	 important	 players	 in	innate	immunity	they	are	also	susceptible	to	exploitation	by	viruses	such	as	HIV.		
	






Amongst	the	different	NOD-like	receptors,	NLRP3	(NOD-like	receptor	family,	pyrin	domain-containing	3)	appears	to	act	as	an	indirect	sensor	of	viral	invasion.	NLRP3	recognises	 adenovirus	 (dsDNA	 virus)(21),	 Sendai	 virus	 (ssRNA	 virus)(22),	 and	Influenza	 A	 virus	 (ssRNA	 virus)(23).	 Upon	 activation,	 NLRP3	 oligomerises	 and	recruits	ASC	and	procaspase-1	to	form	the	inflammasome	complex.	This	complex	activates	 caspase-1	 which	 in	 turn	 leads	 the	 conversion	 of	 IL-1β	 and	 IL-18	precursors	to	fully	functional	IL-1β	and	IL-18(19).			
	






MDA5/LGP2	(27).	Regardless	of	the	pathway	of	stimulations	by	the	different	PRRs,	one	 common	 factor	 following	 activation	 of	 these	 receptors	 is	 the	 induction	 of	interferon	and	interferon	induced	genes	to	combat	infections(28).	
	Figure	 1.	 Viruses	 are	 recognised	by	 Intracellular	Pattern	Recognition	Receptors	 (PRR).	 In	their	 inactive	 state,	 RIG-1,	 MDA5	 are	 phosphorylated.	 Upon	 recognition	 of	 viral	 RNA,	 they	 are	dephosphorylated	by	phosphoprotein	phosphatase	1	α	and	γ	(PP1α/γ).	Their	phosphorylation	and	consequent	 activation	 results	 in	 conformational	 changes	 in	 both	 receptors.	 RIG-1	 C-terminal	domain	 binds	 to	 5’ppp	RNA	 and	wraps	 around	RNA	molecules	 through	 non-specific	 phosphate	sugar	interactions	in	the	RNA	backbone.	MDA5	binds	to	long	dsRNA	(>1000bp)	and	assembles	into	filaments	with	the	RNA	molecules.	LGP2	has	similar	CTD	structure	to	RIG1	and	MDA5	and	binds	to	the	 termini	of	dsRNA	molecules.	The	 juxtapositions	of	 these	molecules	activate	MAVS	signalling	culminating	with	the	induction	of	interferon	genes.	Protein	kinases	Cα/β	act	as	regulators	of	RIG-1	signalling	 by	 phosphorylation.	 On	 the	 other	 hand,	 USP21	 regulates	 RIG-I	 signalling	 by	 de-ubiquitination.	Upon	binding	of	RNA	or	DNA	in	the	endosomal	lumen,	TLRs	dimerise	and	undergo	conformational	changes.	These	conformational	changes	allow	protein	kinases	to	phosphorylate	two	tyrosine	residues	in	TLRs	receptors	that	trigger	TLR	activation	and	recruitment	of	adapter	proteins.	Similar	to	other	PRR	pathways,	recognition	of	viral	species	leads	to	the	induction	of	the	interferon	genes.	(Figure	was	constructed	using	information	from	Mogensen,	et	al.,	2008	(3)	and	Fernstel,	et	
al.,	2015	(29).			
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1.1.2.				Activation	of	interferon	upon	infection		Several	 studies	 have	 shown	 that	 interferons	 are	 crucial	 for	 the	 antiviral	defence	 of	 the	 organism.	 One	 of	 the	 first	 reports	 of	 interferon	 activity	 was	published	back	in	1957	by	Isaacs	and	Lindenmann	when	they	observed	that	the	supernatant	 from	 chicken	 cells	 exposed	 to	 heat-inactivated	 influenza	 virus	‘interfered’	with	the	infection	of	other	cells(30).	Since	their	discovery,	Type	I	interferon	IFN-α/β	have	been	found	to	be	one	of	the	first	and	most	important	cytokines	produced	to	fight	infections.	For	example,	wild	type	adult	129	Sv/Ev	mice	challenged	with	Sindbis	virus	strain	TR339	show	only	mild	symptoms	due	to	 functional	 IFN-α/β	 receptors.	 In	 contrast,	 129	 Sv/Ev	mice	 carrying	 non-functional	IFN-α/β	receptors	genes	die	soon	after	being	infected	by	the	same	strain(31).	There	are	many	Type	I	 interferons	in	humans	(IFN-α,β,e,k,w)	and	they	 all	 bind	 to	 a	 common	 cell	 surface	 receptor:	 type	 I,	 interferon	 receptor	(Figure	2).		Similarly,	type	II	interferon	gamma	(IFN-g)	was	originally	discovered	due	to	its	capacity	to	‘interfere’	with	pathogen	infections(32).	IFN-g	role	is	reflected	by	the	susceptibility	of	C57BL/9	mice	with	defective	IFN-γ	gene	to	Mycobacterium	
bovis	 bacillus	 Calmette–Guérin	 (BCG)	 infection(33).	 Typically,	 defects	 in	 the	IFN-γ	pathway	due	to	mutations	in	IFN-γ	receptor	1	are	characterised	by	severe	viral	and	bacterial	infections.	In	a	case	study	by	Jouanguy	and	colleagues,	it	was	described	how	inoculation	of	live	BCG	vaccine,	the	most	widely	used	vaccine	at	the	 time,	 proved	 fatal	 for	 a	 two-and-a-half-month	 girl,	 homozygous	 for	 a	mutation	in	IFN-γ	receptor.	In	normal	circumstances,	the	attenuated	strain	of	


















levels	of	HVC	viral	 load	observed	 in	some	patients.	High	 levels	of	 ISGs	upon	IFNλ4	 expression,	 including	 USP18	 and	 ISG15	 will	 act	 through	 a	 negative	feedback	mechanism	to	block	endogenous	IFNα	pathway	and	will	contribute	to	the	 desensitisation	 of	 liver	 cells	 to	 administered	 IFNα(44)	 resulting	 in	 poor	treatment	response.		Ultimately,	IFNls	together	with	IFNα	and	IFNβ	can	induce	over	100	interferon	stimulated	genes	(ISGs)	following	virus	infection(47).			












http://www.gwascentral.org/,	 last	 accessed	 on	 February,	 2017)	 of	 infectious	diseases.	A	candidate	gene	study	in	a	cohort	of	hospitalised	patients	infected	with	West	Nile	virus	(WNV)	in	the	USA	reported	that	a	polymorphism	(rs3213545)	in	
OAS	was	 more	 frequently	 found	 in	 cases	 compared	 to	 controls	 (P=0.004)(52).	However,	 the	 P-value	 was	 not	 genome-wide	 significant	 (5x10-8)	 and	 the	 low	number	of	cases	(n=33)	and	controls	(n=60)	included	in	the	study,	suggests	that	the	signal	would	need	to	be	tested	in	other	cohorts.			Other	 examples	 of	 interferon	 inducible	 genes	 with	 important	 roles	 in	 virus	restriction,	are	the	Interferon	transmembrane	(IFITM)	genes.	These	genes	IFITM1,	
IFITM2	and	IFITM3	were	discovered	over	a	decade	ago	but	interest	in	their	role	as	antiviral	 factors	 re-emerged	 following	 an	 RNAi	 screen	 that	 identified	 over	 100	genes	 involved	 in	 influenza	 A/B	 and	 dengue	 2	 (New	 Guinea	 C	 strain)	restriction(53).	In	this	RNAi	screen	it	was	discovered	that	depletion	of	IFITM3	in	osteosarcoma	 cells	 (U2OS	 cells)	 caused	 an	 increase	 in	 influenza	 A	 (A/Puerto	Rico/8/34	 H1N1-PR8	 strain)	 infection	 whereas	 overexpression	 of	 all	 three	proteins	(IFITM1,2	and	3)	resulted	in	the	restriction	of		influenza	A,	dengue	2	(New	Guinea	C	strain)	and	West	Nile	virus	(strain	2741)	infections(53).		
In	 vivo	studies	have	also	established	 IFITMs	 role	as	antiviral	 restriction	 factors.	Two	groups	set	out	to	characterise	the	susceptibility	of	ifitm3-/-	mice	to	influenza	A	infections	using	low	pathogenicity	virus	(A/X-31)(54)	and	2009	H1N1	pandemic	strain	(A/09	Eng/195)(55).	Everitt	and	colleagues	found	that	ifitm3-/-	mutant	mice	exhibited	rapid	loss	of	body	weight	(>25%)	by	day	6	and	had	to	be	euthenised(54).	By	contrast,	wild	type	mice	lost	<25%	of	their	body	weight	and	fully	recovered(54).	Bailey	 and	 colleagues	 also	 reported	 weight	 loss	 >20%	 in	 both	 ifimt3−/−	 and	







IFITM	genes	 	Members	 of	 the	 IFITM	 gene	 family	 in	 humans	 are	 located	 within	 30kb	genomic	stretch	in	chromosome	11	at	position	11:298,205-327,846.	Only	IFITM1,2	and	3	have	been	reported	as	important	restriction	factors	in	viral	infections.	The	other	two	members	of	the	family,	IFITM5	and	IFITM10	have	no	reported	roles	as	viral	restrictors	and	their	functions	will	not	be	addressed	in	this	work.	There	is	a	high	 level	of	 amino	acid	homology	between	 some	of	 the	members	of	 the	 IFITM	protein	family	in	different	species	and	high	levels	of	amino	acid	similarity	(>90%),	between	human	IFITM2	and	IFITM3	(Figure	3).	In	mice,	the	IFITM	family	include	
IFITM1,2,3,5,6	 (fragilis	 2-6)	 on	 chromosome	 7(56).	 Other	 paralogous	 and	orthologous	genes	have	been	reported	in	mammals	including	marsupials(57).			
	Figure	 3.	Amino	 acid	 alignment	 for	 IFITM	 proteins	 in	 human	 and	mouse	 using	 CLUSTAL	






IFITM1,	 2	 and	3	 also	 share	 a	 common	CD225	domain	 and	 although	 there	 is	 no	resolved	 structure	 for	 the	 IFITM	proteins,	NMR	studies	have	proposed	a	model	where	the	N-terminal	domain	(NTD)	is	located	in	the	cytoplasm	and	the	C-terminal	domain	is	in	the	extracellular	space	(Figure	4).			





























1.1.5.				Broad	Spectrum	antiviral	function	of	IFITM	proteins	 	The	differences	in	cellular	localisation	are	reflected	in	the	distinct	antiviral	functions	reported	for	IFITM	proteins,	in	vitro.	Restriction	of	Hepatitis	C	virus	is	greater	 in	cells	 that	overexpress	 IFITM1,	compared	 to	 IFITM2	or	 IFITM3(64-66).	 IFITM1	protein	 is	expressed	 in	 the	plasma	membrane	where	 it	 interacts	with	the	cell	surface	protein	CD81(67).	Previous	studies	have	established	that	both	 IFITM1	 (previously	 known	 as	 Leu	 13)	 and	 CD81	 (previously	 known	 as	TAPA-1)	 are	 associated	 noncovalently	 in	 the	 plasma	membrane(67).	 This	 is	relevant	 for	 IFITM1	 HCV	 antiviral	 function	 because	 CD81	 is	 a	 cell	 surface	tetraspanin	 that	 directly	 interacts	 with	 Hepatitis	 C	 virus	 E2	 protein	 during	infection(65,	68).	Wilkins	and	colleagues	observed	that	IFITM1	is	 localised	in	hepatic	 tight	 junctions	where	 they	disrupt	 the	 interactions	between	HCV	and	cell	 plasma	 membrane	 proteins	 such	 as	 occluding	 and	 CD81(65).	 Although,	IFITM2	and	3	have	also	been	reported	to	restrict	infection,	it	seems	that	IFITM1	restricts	the	virus	with	greater	potency	compared	to	 its	counterparts(66).	By	contrast,	 there	 is	no	observed	 inhibition	of	 infection	by	 IFITM1	of	other	RNA	viruses	such	as	Sindbis	 (SINV)	or	Semliki	Forest	virus	 (SFV)(69).	At	 least	 for	Semliki	 Forest	 virus,	 the	 lack	 of	 IFITM1	 restriction	may	 be	 explained	 by	 the	endocytic	uptake	and	fusion	of	SFV	with	early	endosomes	which	enables	it	to	escape	restriction(69).		The	patterns	of	restriction	of	IFITM2	and	3	are	similar;	although	most	studies	report	a	more	potent	inhibition	of	infection	by	IFITM3(53,	54,	70).	Studies	in	

























IFITM	protein Cell	Line Model Level	of	restriction Reference
Enveloped
Orthomyxoviridae Influenza	A	virus    P	L M1–3 A549 Overexpression M1	-	85%
M2	-	75%	 Brass	et	al. 	2019
M3	-	80%
Flaviviridae West	Nile	virus   P M1–3 Vero	E6 Overexpression M1	-	85%
M2	-	70%	
M3	-	90% Brass	et	al. 	2019
Yellow	Fever	virus   P M1–3 Vero	E6 Overexpression M1	-	75%
M2	-	55%	
M3	-	80%
Hepatitis	C	virus   P	 M1 Huh7 Overexpression M1	-	99% 	Wilkins	et	al.,	2013
Dengue	virus  x P M3 Hela Depletion	(siRNA) No	restriction Brass	et	al. 	2019
Rhabdoviridae Vesicular	
stomatitis	virus











Ebola	virus Δ  P	L M1–3 M1	-	90%
M2	-	80%	
M3	-	90%
Coronaviridae SARS	coronavirus Δ  P	L M1–3 Vero	E6 Overexpression M1	-	90%
M2	-	80%	 Huang	et	al.,	2011
M3	-	70%












HIV-1 x x	 P M3 Hela-CD4	
cells
Overexpression No	restriction Brass	et	al. 	2019
Jaagsiekte	sheep	
retrovirus
   P M1	 HTX Overexpression M1	-	60% Li	et	al.,	2013
Moloney	
leukaemia	virus
× × P	L No Vero	E6 Overexpression No	restriction Brass	et	al. 	2019
Arenaviridae Lassa	virus  × P No Vero	E6 Overexpression No	restriction




 × P No Vero	E6 Overexpression No	restriction
Alphaviridae Semliki	Forest	
virus
   L M2	and	M3	best A549 Overexpression M2-	60% Weston	et	al.,	2016
M3-	90%
Bunyaviridae Hantaan	virus   L M1-3 Vero	E6 Overexpression M1	-	30%
M2	-	30%	
M3	-	30%











 × L No Vero	E6 Overexpression No	restriction




















	Figure	6.		Mechanism	of	restriction	of	IFITM	proteins.	IFITM2	and	IFITM3	proteins	are	expressed	in	 the	endosomes	 (vesicles	 in	purple)	 and	 restrict	 a	number	of	 viruses	entering	 the	 cell	 via	 the	endosomal	pathway.	The	green	vesicle	=	lysosome.		Importantly,	 the	 research	 into	 the	 mechanisms	 of	 restriction	 provide	 some	indication	 of	 the	 therapeutic	 potential	 of	 IFITM	 proteins.	 These	 proteins	 act	throughout	 the	 early	 restriction	 steps	 and	 this	 suggests	 that	 the	 escape	mechanisms	 generally	 employed	 by	 viruses	 will	 not	 be	 as	 effective	 upon	 their	expression.	For	instance,	viral	proteins	generated	after	viral	entry	and	replication	such	as	HIV-1	viral	infectivity	factor	(Vif)	and	viral	protein	U	(Vpu),	allow	the	virus	to	evade	host	responses	by	degrading	restriction	factors	such	as	Apolipoprotein	B	MRNA	Editing	Enzyme	Catalytic	Subunit	3G	 (APOBEC3G)(80)	and	Tetherin(81),	respectively.	 In	 contrast,	 IFITM-mediated	 restriction	 precedes	 viral	 replication,	thus,	there	is	 little	opportunity	for	the	synthesis	of	de	novo	viral	 inhibitors.	This	suggests	that	unless	the	virion	carries	a	mutation	that	counteracts	IFITM-mediated	restriction,	it	will	be	challenging	for	the	virus	to	evade	restriction(76).	As	a	direct	result	of	 these	observations,	 several	groups	have	attempted	 to	demonstrate	 the	
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expression	of	a	truncated	IFITM3	protein	lacking	the	first	21	amino	acids	due	to	the	use	of	an	alternative	start	codon(54).		Other	genetic	studies	soon	followed	(Table	2)	confirming	similar	findings	in	Asian	populations	where	the	frequency	of	rs12252	is	much	higher	(MAF	=	0.53).	These	groups	reported	associations	to	not	only	influenza	H1N1(87,	88)	infections	(n=83,	OR=6.4)	but	also	 for	HIV(89)	(n=178,	OR=3.8)	and	Hantaan(90)	(n=69,	OR=2.1)	virus	 infections.	 For	 example,	 Zhang	 and	 colleagues,	 analysed	 the	 association	between	the	rs12252	SNP	and	H1N1	influenza	in	a	Chinese	cohort	(n=35	cases	of	severe	influenza	and	n=48	control	patients	displaying	symptoms	of	mild	flu)(88).	This	 study	 reported	 an	 association	 between	 homozygotes	 for	 the	 C	 allele	 and	severe	 influenza	 when	 compared	 to	 the	 mild	 control	 population	 (P=0.0002,	OR=6.4).	Specifically,	they	found	that	69%	of	hospitalised	patients	suffering	from	severe	 flu	 carried	 the	 CC	 alleles	 compared	 to	 25%	 of	 patients	 suffering	 mild	symptoms.	As	a	consequence,	they	concluded	that	rs12252	associates	with	severe	H1N1	influenza.			Table	2.	Reported	associations	for	IFITM3	rs12252	





































reduction	 in	viral	 load(102).	This	SNP	 is	 situated	near	 the	HLA	complex	5	gene	which	 is	 in	 complete	 LD	with	 HLA-B*57,	 already	 known	 to	 be	 protective	 from	reports	by	a	previous	candidate	gene	study(98).	Another	association	was	reported	for	rs9264942	(P	=	3.77	×	10−9),	located	35kb	form	HLA-C	gene(102).		Replication	studies	 in	a	 larger	number	of	 individuals	confirmed	these	findings	and	reported	new	nominally	significant	associations	for	rs9468692	(P	=	3.6	×	10−5)	located	at	3’	region	 of	 TRIM10	 and	 the	 non-synonymous	 SNPs	 rs8192591	 (P	 =	 5.5	 ×	 10−5)	located	in	coding	region	of	NOTCH4	gene(103,	104).	A	recent	GWAS	on	6,315	HIV	positive	European	individuals	also	confirmed	the	central	role	of	the	MHC	region	in	HIV	 susceptibility	 and	 progression(99).	 In	 this	 study,	 they	 mapped	 MHC	association	signals	to	a	peptide-binding	groove	of	HLA-B	and	HLA-A	regions(99).	Interestingly,	 the	 authors	 also	observed	a	 strong	association	between	CCR5D32	with	 reduced	 set-point	 viral	 load	 (P=1.6x10-16)	 and	 reported	 that	 seven	 other	markers	 overlapping	 the	 CCR5	 region	 appear	 to	 tag	 variants	 distinct	 from	CCR5D32,	 suggesting	 the	 presence	 of	 other	 causal	 variants	 that	 are	 yet	 to	 be	discovered(99).		Further	successes	of	GWA	studies	have	been	reported	for	other	infectious	diseases	such	as	tuberculosis	(TB).	In	one	of	the	largest	genetic	studies	of	TB	so	far,	Curtis	and	colleagues	genotyped	5,530	individuals	with	pulmonary	TB	and	5,607	healthy	controls(105).	They	 found	one	association	 in	ASAP1,	a	gene	that	encodes	an	Arf	GTPase-activating	 protein	 (Arf	 GAP).	 Meta-analysis	 using	 published	 data	 from	Ghanaian	(971	TB	cases	and	988	controls)	and	Gambian	(1,306	TB	cases	and	1,372	controls)	 cohorts	 validated	 these	 findings.	 Furthermore,	 functional	 analysis	 of	dendritic	 cells	 showed	 that	when	 these	 cells	were	 infected	with	Mycobacterium	
bovis	BCG,	this	led	to	the	reduction	of	ASAP1	expression.	In	addition,	homozygotes	of	 the	allele	A	at	 rs10956514,	which	was	associated	with	higher	TB	risk	 in	 this	study,	 displayed	 a	 stronger	 reduction	 of	 ASAP1	 expression	 following		






Other	 genome-wide	 studies	 have	 served	 to	 validate	 previous	 associations.	 For	example,	in	a	GWAS	of	severe	malaria	(n=1,060	cases	and	n=1,500	controls)	from	The	 Gambia,	 Jallow	 and	 colleagues(106)	 reported	 that	 their	 strongest	 signal	 of	association	was	near	the	haemoglobin	beta	(HBB),	the	gene	that	contains	the	sickle	haemoglobin	 variant	 haemoglobin	 S	 (HbS)	 polymorphism	 rs334.	 This	polymorphism	results	in	a	non-synonymous	protein	change	where	a	glutamic	acid	in	the	β-globin	chain	is	replaced	by	the	amino	acid	valine.	Homozygotes	for	this	mutation	experience	life-threatening	disease	due	to	sickle	cell	anaemia,	whereas	heterozygotes	have	a	tenfold	reduced	risk	of	severe	malaria(107).		Unfortunately,	the	 authors	 did	 not	 find	 any	 new	 loci	 that	 reached	 genome-wide	 significance,	although	they	did	report	nominal	associations	for	rs6503319	(trend	test	OR	=	1.21,	











































The	availability	of	reference	panels	has	also	contributed	to	advances	in	statistical	tests	such	as	genotype	imputation,	that	are	now	commonly	used	in	genome-wide	studies(123).	 Typically,	 imputation	 algorithms	 rely	 on	 the	 identification	 of	haplotypes	(how	SNPs	are	arranged	along	the	chromosome)	using	typed	SNPs	in	the	 study	 individuals	 that	 can	 then	 be	 used	 to	 scan	 similar	 haplotypes	 in	individuals	in	the	reference	panel.	Algorithms	use	this	sharing	to	predict	missing	alleles	 in	 the	 study	 individuals	 that	 are	 not	 directly	 genotyped	 by	 the	microarray(106)	 but	 exist	 in	 the	 reference	 panel	 within	 a	 similar	 haplotype	context.	 These	 in	 silico	 imputed	 SNPs	 can	 boost	 the	 power	 of	 the	 GWAS	 by	increasing	 the	number	of	SNPs	 that	 can	be	 tested	 for	association.	Therefore,	 an	association	signal	can	result	from	directly	genotyped	or	imputed	SNPs.		






To	compare	genotyping	arrays,	it	is	common	practice	to	consider	what	proportion	of	 SNPs	 can	be	directly	 genotyped	by	 the	 array	 and	how	many	 variants	 can	be	‘captured’	by	markers	in	the	chip.	It	has	been	demonstrated	that	in	theory,	500K	maximally	efficient	tag	SNPs	could	capture	nearly	80%	of	common	variation	in	CEU	and	JPN	+	CHB	populations	and	70%	of	variation	in	YRI	population	at	a	correlation	coefficient	(r2≥0.8)(115).	It	is	this	proportion	of	total	variants	‘captured’	or	‘tagged’	at	a	given	correlation	threshold	(r2≥0.8)	by	SNPs	in	the	array	which	is	referred	to	as	 global	 coverage	 of	 the	 chip	 and	 constitutes	 one	 important	 metric	 for	 chip	selection	and	study	design.			Typically,	estimations	of	coverage	set	an	arbitrary	threshold	(usually	at	r2≥0.8)	to	find	correlations	between	markers	in	the	genotype	array	and	variants	in	a	specific	reference	panel	(HapMap	or	1KGP)	using	the	following	formula:		


















2.3.				Materials	and	Methods		2.3.1.				Choosing	genotyping	arrays		I	 chose	 to	 analyse	 genotyping	 arrays	 used	 in	 previous	 genetic	 studies	 of	infectious	 diseases	 (Table	 3)	 	 for	 HIV(127,	 128),	 	 chronic	 hepatitis	 C(38)	 and	dengue(113),	listed	in	the	GWAS	Central	http://www.gwascentral.org/	and	GWAS	catalogue	https://www.genome.gov/26525384	on	(December,	2015).	Because	the	majority	of	these	arrays	have	been	retired	from	the	market,	I	also	chose	to	calculate	coverage	of	more	recent	genotyping	chips.	Table	3	lists	all	chips	analysed	and	the	number	of	markers	included	in	each.			The	first	step	of	my	analysis	involved	making	a	list	of	chromosomal	positions	of	all	markers	included	in	the	array	from	http://www.well.ox.ac.uk/~wrayner/strand/,	the	 Wellcome	 Trust	 Sanger	 ‘in-house’	 repositories	 and	http://www.affymetrix.com/catalog/prod350001/AFFY/.	 All	 annotation	 files	were	updated	to	Version	3	NCBI	Build	37	of	the	human	genome.		Table	3.	List	of	all	the	genotyping	arrays	analysed		
				
Column1 Column2 Column3 Column4 Column5
Number	of	SNPs Targeted	MAF Based	on
Illumina
Illumina	550 547,327 5.0% HapMap
Human670-QuadCustom_v1_A 654952 5.0% HapMap
Human660W-Quad_v1 657,366 5.0% HapMap
Human	OmniExpress-24	 713,014 5.0% HapMap
HumanHap	1M-Duo_v3 1,199,187 5.0% HapMap
Human	Omni1S 1,185,076 2.50% 1KGP*,	HapMap
Human	Omni2.5S-8 2,015,318 1.0% 1KGP
Infinitum	Human	Omni5-4	v1.1 4,284,426 1.0% HapMap,	1KGP
Affymetrix	
Affymetrix	500K	** 500,568 5.0%
Affymetrix	6.0 906,600 5.0% HapMap	and	previous	Mapping	500K	and	SNP	5.0	Arrays














Where:	(	 represents	 the	 number	 of	 common	 SNPs	 (MAF	³	 1%)	 per	 population	 on	 the	genotyping	array.	I	made	a	list	of	these	positions	from	the	information	provided	in	the	annotation	files	for	each	chip		9	denotes	the	number	of	SNPs	not	on	the	microarray	but	which	are	tagged	at	r2≥	0.8	by	at	least	one	marker	on	the	chip	within	a	1000kb	window.	To	find	all	proxy	SNPs,	I	used	the	LD	options	in	PLINK	(v1.9).	Output	SNPs	were	filtered	by	MAF	(³	1%).	I	also	excluded	all	SNPs	included	in	microarrays	as	‘tag’	SNPs.		:	represents	the	number	of	autosomal	SNPs	(MAF	³	1%)	identified	in	Version	3	NCBI	 Build	 37	 of	 1000	 Genomes	 phase	 1	 project.	 To	 calculate	 the	 number	 of	variants	per	population,	I	used	PLINK	(v1.9)	with	the	following	command:	plink	--allow-no-sex	--write-snplist	--geno	0.1	–exclude	INDELS.		










































European 0.56 0.66 0.59 0.64 0.68 0.64 0.61 0.84 0.50 0.64 0.73
Asian 0.62 0.70 0.63 0.67 0.69 0.63 0.55 0.75 0.52 0.65 0.73






2.4.2.				A	map	of	genome-wide	gene	coverage		I	estimated	the	coverage	of	IFITM2	and	IFITM3	in	eight	Illumina	genotype	arrays	 and	 three	 Affymetrix	 chips	 (Table	 5).	 In	 order	 to	 ascertain	 how	 the	coverage	 for	 the	 IFITM	 genes	 compared	 to	 other	 genes	 genome-wide,	 I	 also	calculated	 the	 coverage	 of	 a	 further	 15,635	 protein-coding	 genes.	 The	motivation	 behind	 these	 calculations	 was	 to	 assess	 how	 the	 coverage	 for	







IFITM2	or	IFITM3.			Coverage	 analysis	 shows	 that	 denser	 genotyping	 arrays	 such	 as	HumanOmni2_5,	HumanOmni5_4	and	Affymetrix	Axiom	Pan	African	provide	better	 coverage	 across	 populations.	 Close	 examination	 of	 tagging	 SNPs	included	 in	these	arrays,	shows	that	 the	 increase	 in	coverage	 is	 the	result	of	introducing	a	greater	number	of	 tag	SNPs	 in	 the	 IFITM	 region.	This	suggests	that	in	order	to	capture	variation	in	the	IFITM	region,	SNPs	would	need	to	be	genotyped	 directly;	 undoubtedly	 limiting	 the	 usefulness	 of	 using	 tagging	strategies	for	this	locus.			It	is	common	practice	as	part	of	the	GWAS	analysis	to	use	imputation	to	boost	statistical	power.	Simulations	studies	have	shown	that	imputation	can	improve	the	performance	of	genotyping	arrays	even	when	the	coverage	of	such	arrays	is	low	(<50%).	Imputation	methods	such	as	IMPUTE2	provide	a	probabilistic	prediction	at	each	imputed	genotype	given	by	the	‘INFO’	score(123)	that	allows	researchers	 to	 filter	 out	 poorly	 imputed	 sites.	 	 Another	 imputation	 quality	assessment	 commonly	 used,	 involves	 measuring	 the	 squared	 correlation	between	the	best-guess	genotype	and	the	true	genotype(131)	to	give	a	single	measure	r2.	 I	used	both	these	metrics	to	assess	the	imputation	quality	in	the	









































Coverage for Illumina genotyping arrays
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in	 286	 European	 individuals	 from	 the	 IBS,	 GBR,	 TSI	 and	 CEU	 1000	 Genomes	 Project	
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Genotype	Platform	 African	 Asian	 European	 African	 Asian	 European	Illumina	550	 6	 12	 9	 0	 0	 5	Illumina	660W-Quad_v1	 6	 12	 9	 2	 2	 8	Human670-QuadCustom_v1_A	 6	 12	 9	 2	 2	 8	Human	OmniExpress-24	 6	 12	 12	 8	 14	 27	Human	Omni1S_H	 6	 22	 18	 10	 20	 15	HumanHap	1M-Duo_v3	 20	 34	 26	 18	 22	 39	Human	Omni2.5S-8_B	 16	 34	 24	 5	 6	 15	Infinitum	Human	Omni5-4	v1.1	 16	 34	 29	 18	 24	 40	Affymetrix	500K	 0	 0	 0	 0	 0	 0	Affymetrix	SNP6.0	 30	 44	 32	 12	 8	 24	Axiom_Pan_African	 8	 28	 18	 6	 20	 10		
	Figure	11.	INFO	scores	and	r2	imputation	quality	metrics	for	the	IFITM	region.	(a)The	black	line	represents	 the	 average	 INFO	 scores	 for	 different	 allele	 frequency	 bins	 in	 6,000	 European	individuals	 genotyped	 using	 Omni2.5	 array	 from	 a	 recent	 GWAS	 of	 Primary	 Sclerosis	Cholangitis(129).	The	 INFO	scores	 for	 these	 individuals	 is	1.5X	 less	 than	 the	predicted	genome-wide	INFO	scores	for	SNPs	at	the	specified	allele	frequency	bins.	(b)	The	black	line	represents	the	average	r2	scores	 for	different	allele	 frequency	bins	 in	 the	same	6000	 individuals.	Similar	 to	 the	INFO	scores,	the	r2	is	1.5X	less	than	the	predicted	genome-wide	r2	scores	for	SNPs	at	the	specified	allele	 frequency	 bins.	 Error	 bars	 represent	 the	 standard	 error	 of	 the	mean	 for	 the	 INFO	 and	 r2	values.					





































































3.				Targeted	sequencing	of	the	IFITM	locus		3.1.				Introduction	 	In	the	previous	chapter,	I	established	that	IFITM2	and	IFITM3	are	amongst	7%	of	all	protein	coding	genes	with	less	than	25%	common	variant	(minor	allele	frequency	 >	 0.05)	 coverage	 across	 all	 arrays.	 Furthermore,	 all	 attempts	 to	characterise	 IFITM	 variation	 by	 sequencing	 have	 focused	 on	 sanger	 sequencing	one	SNP	(rs12252),	located	at	5’	end	of	IFITM3.			
In	 this	 chapter,	 I	 employ	 a	 targeted	 sequencing	 method	 using	 two	 different	sequencing	 technologies:	 Illumina	MiSeq	and	PacBio	 sequencing	 to	 characterise	



















Importantly,	 both	 array	 and	 solution-base	 captures	 have	 been	 adapted	 for	technologies	 that	 required	PCR	amplification	 steps	 for	 their	 library	preparation	(Illumina	 MiSeq).	 Only	 recently,	 however,	 several	 laboratories	 have	 started	 to	adapt	 the	 targeted	 sequencing	 method	 to	 make	 it	 compatible	 with	 other	technologies	such	as	PacBio	RS	(151,	152)	to	define	structural	variation	in	regions	of	 the	 genome	 or	 to	 use	 for	 de	 novo	 assemblies	 of	 repetitive	 plant	 genomes.	Typically,	 PacBio	 has	 been	 used	 successfully	 to	 characterise	 regions	 with	 high	levels	of	 sequence	 similarity	 that	 cannot	be	 accurately	mapped	with	 short-read	technologies	(153,	154)			



























	Figure	15.	Single-molecule	real-time	(SMRT)	sequencing	from	Pacific	Biosciences	(PacBio).	SMRTbell	 libraries	 are	 loaded	 to	 a	 SMRT	 cell	 that	 contains	 tens	 of	 thousands	 of	 zero-mode	waveguides	(ZMW).	Each	ZMW	well	is	illuminated	from	below,	but	the	light	wavelength	is	too	large	to	go	all	the	way	through	the	well.	Thus,	attenuated	light	penetrates	the	lower	20-30nm	of	the	well	and	creates	a	detection	volume.		A	DNA	template-polymerase	complex	is	immobilized	at	the	bottom	of	this	ZMW	well,	in	the	detection	volume.	A	mixture	of	labelled	nucleotides	is	added	to	the	SMRT	cell	and	as	each	nucleotide	is	held	at	the	detection	volume	by	the	enzyme’s	active	site,	a	light	pulse	is	 produced.	 During	 the	 nucleotide	 incorporation,	 the	 phosphate	 group	 is	 cleaved	 and	 the	fluorophore	attached	to	the	nucleotide	diffuses	away.	This	process	occurs	in	parallel	within	each	of	the	tens	of	thousands	of	ZMW	wells	that	make	up	the	SMRTcell.	Figure	adapted	from	Goodwin,	et	
al.,	2016(155).		The	PacBio	RS	has	the	advantage	of	producing	long	sequencing	reads.	For	example,	it	can	generate	average	polymerase	reads	of	10-15kb	in	length	which	are	ideal	for	




































































Lymphoblastoid	cell	lines	(LCL)	from	nine	unrelated	individuals	(Table	6)	included	in	the	1000	Genomes	Project	and	distributed	by	Coriell	Cell	Repository	were	 selected	 for	 this	 study.	 These	 cells	 were	 maintained	 in	 RPMI	 1640	 plus	Glutamax	 medium	 (61870-010,	 Invitrogen)	 supplemented	 with	 20%	 v/v	 Fetal	Bovine	Serum	(FBS	Biosera)	and	incubated	at	37oC	in	5	%	CO2.	LCLs	were	passaged	twice	a	week	(1:10	split).	Genomic	DNA	was	extracted	from	these	LCLs	using	Blood	and	Cell	culture	kits	(Qiagen,	Germany)	following	the	manufacturer’s	instructions.	Because	the	purified	DNA	was	subsequently	used	for	targeted	sequencing	of	the	






















established	that	100%	similarity	of	a	continuous	25bp	region	was	sufficient	for	off-target	hybridisation	(Personal	communication	with	Agilent	representatives).		For	the	second	phase	of	the	study,	I	used	the	same	probe	library	as	a	backbone	and	excluded	a	number	of	probes	with	 ‘hits’	on	several	 chromosomal	 regions	of	 the	genome.	 The	 final	 probe	 design	 for	 the	 region	 (ELID	 0695421),	 still	 contained	probe	sequences	spanning	repetitive	regions	but	in	less	numbers.	This	left	a	total	of	 3,198	 probe	 sequences,	 covering	 around	 81.6%	 of	 my	 region	 of	 interest	(Chr11:280,000-380,000).	All	the	data	shown	in	this	chapter	is	the	result	of	this	last	pulldown	pilot	experiment.		Table	7.	Table	representing	the	pulldown	efficiency	of	three	initial	samples	used	in	the	study	


















I	 purified	 and	 size	 selected	 the	 DNA	 by	 adding	 0.6X	 Agencourt	 AMPure	beads	 (Beckman	Coulter)	 to	 120µl	 of	 sheared	 genomic	DNA.	 The	 quality	 of	 the	sheared	libraries	was	assessed	by	running	samples	on	the	Agilent	2100	Analyser	(Agilent	Technology,	California,	USA).	This	was	followed	by	end	repair	steps,	dA-tailing	of	3’	ends	of	the	genomic	DNA	and	ligation	of	sequencing	adaptors	following	the	 SureSelect	 XT	 Target	 Enrichment	 System	 instructions	 (Agilent	 Technology,	California,	USA).		
Amplification	of	DNA	libraries	
The	 PCR	 conditions	 for	 library	 amplification	 were	 optimised	 to	 fit	 the	fragment	 sizes	 of	 the	 genomic	 DNA	 (Table	 8)	 to	 enable	 the	 amplification	 of	fragments	 ³	 3kb	 with	 the	 lowest	 number	 of	 cycles.	 The	 low	 number	 of	 cycles	ensures	 the	 minimal	 number	 of	 PCR	 type	 errors	 being	 introduced.	 	 For	 the	amplification	reaction,	 I	used	Herculase	II	Fusion	DNA	Polymerase	enzyme	with	the	following	conditions:	






2. Hybridisation	of	genomic	DNA	and	probe	libraries	I	prepared	each	DNA	library	to	a	concentration	of	221ng/µl,	in	a	final	volume	of	3.4µl.	I	then	added	5.6µl	of	SureSelect	block	mix	to	avoid	hybridisation	of	probes	to	library	indexes.	This	was	followed	by	the	addition	of	40µl	of	hybridisation	buffer	and	 2µl	 of	 SureSelect	 RNA	 probes	 (capture	 baits	 ELID	 number	 0695421).	 The	hybridisation	reaction	was	left	on	a	thermal	cycler	at	65°C.	After	18hrs,	 I	added	200µl	of	a	mixture	of	Dynabeads	MyOne	Streptavidin	T1	and	SureSelect	Binding	Buffer	 to	 the	 hybridisation	 reaction.	 With	 my	 captured	 DNA	 retained	 on	 the	streptavidin	 beads,	 I	 then	 proceeded	 to	 purify	 and	 concentrate	 the	 hybridised	library	to	a	final	30µl	volume.	
3. Amplification	of	hybridised	libraries	
I	 used	 14µl	 of	 the	 Biotinylated	 RNA	 library	 hybrids	 for	 the	 amplification	reaction	(Table	9).	This	meant	that	for	every	pulldown	experiment,	I	was	able	to	carry	out	 four	amplification	 reactions	 if	 the	DNA	concentration	 remained	 low.	 I	proceeded	to	amplify	the	DNA	using	Herculase	II	Fusion	DNA	Polymerase	under	the	following	PCR	conditions:	Table	9.	Optimised	PCR	conditions	for	the	PCR	amplification	steps	









The	hybridised	libraries	were	quantified	via	fluorescence	using	Qubit.	This	was	followed	by	end	repair	of	non-phosphorylated	5’	ends	PCR	products	and	sample	purification.	 I	 then	 ligated	 blunt	 hairpin	 adapters	 following	 manufacturer’s	instructions,	included	in	the	PacBio	template	kit	for	2kb	fragments.	I	carried	out	the	SMRTbell	quality	assessment	using	Agilent	2100	Analyser	(Agilent	Technology,	California,	USA)	and	quantified	the	library	using	Qubit.	Libraries	were	sequenced	using	two	SMRT	cells	per	sample.		
































































I	 aligned	 the	ROI	 for	PacBio	data	and	 Illumina	paired-ends	 reads	 to	 the	Human	Reference	Genome	hs37d5	with	bwa-mem(165).	In	order	to	increase	the	quality	of	downstream	variant	calling,	I	 followed	the	data	processing	guidelines	set	out	by	the	GATK	pipeline.	First,	I	marked	duplicates	and	added	read	group	information	using	Picard	Tools	(http://picard.sourceforge.net).	Using	GATK	version	3.6,	I	re-calibrated	each	base	in	the	bam	file	using	a	process	known	as	Base	Quality	Score	Recalibration	(BQSR).	Variant	calling	algorithms	rely	on	the	quality	score	of	each	base	in	the	sequencing	reads.	These	quality	scores	are	generated	by	the	sequencing	machines	 and	 are	 therefore	 subjected	 to	 technical	 errors.	 Base	 Quality	 Score	Recalibration	 (BQSR)	 is	 a	 pre-processing	 step	 developed	 by	 the	 GATK	 team	 in	which	they	adjust	the	quality	scores	per	base	using	external	information	for	known	variants	in	dbSNP	or	1000	Genomes.	Following	recalibration,	I	performed	variant	calling	using	HaplotypeCaller(166)	with	the	following	parameters:	 -ERC	GVCF	--allowNonUniqueKmersInRef	 to	 create	 single	 sample	 gVCFs.	 I	 then	 ran	GenotypeGVCF	to	combine	files	into	one	VCF.	
To	QC	the	raw	variants	for	both	PacBio	and	Illumina,	I	followed	the	hardfiltering	recommendations	stated	by	GATK	(Figure	20).	Due	to	the	low	number	of	samples,	I	could	 not	 apply	 the	 Variant	 Quality	 Score	 Recalibrator	 (VQSR)	 which	 uses	sophisticated	machine	learning	processes	for	the	QC	steps.(167).	The	hardfiltering	parameters	included	were:		
	
QualByDepth	(QD)	metric	that	represents	the	quality	of	the	variant	normalised	by	 the	 allele	 depth	 (AD).	 This	 way	 variants	 in	 high	 depth	 regions	 do	 not	 have	artificially	 inflated	 QUAL	 scores.	 The	 generic	 recommendation	 suggests	 that	variants	with	QD	<2	should	be	filtered	out.		







RMSMapping	 Quality	 (MQ)	 represents	 the	 mean	 mapping	 qualities	 plus	 the	standard	deviation	of	the	mapping	qualities		











































































































	3.4.6.				Sanger	sequencing	validation	of	variants		I	 designed	 the	 primers	 and	 set	 the	 PCR	 conditions	 to	 sequence	 a	 684bp	region	 at	 the	 5’	 end	 of	 the	 IFITM3	 gene	 from	 chr11:320,543-321,227.	 I	 used	primers	 listed	 in	 Table	 13	 and	 Kapa	 HiFi	 (KK2600,	 Kapa	 Biosystems,	 Roche)	polymerase	 for	 the	 PCR	 reaction	 to	 amplify	 the	 DNA	 using	 conditions	 listed	 in	Table	14.			Table	13.	PCR	primers	used	to	target	a	region	at	the	5’	end	of	IFITM3	gene	Name	 Sequence	5’-3’	 Usage	 Manufacturer	
IFITM3_F	 CATTCCCTGGGCCATACG	 target	region	chr11:320,543-321,227	 Metabion,	Germany	
Uni-Alexa555	 CATTCCCTGGGCCATACG-AGAGGTGAGGGCTTTGGGG	 target	region	chr11:320,543-321,227	 Metabion,	Germany					













































Only	15	SNPs	were	reported	only	by	the	Illumina	pulldown	and	none	were	found	to	be	novel	variants.	From	the	35	variants	reported	in	the	PacBio	dataset,	only	6	were	novel	 (Figure	24).	 For	 variants	 reported	by	both	PacBio	 and	 Illumina	not	found	 in	1000	Genomes	(28	SNPs	 in	 total),	only	4	were	novel	 (1	 intronic	and	3	intergenic).	 None	 of	 the	 novel	 variants	 reported	 by	 either	 Illumina	 or	 PacBio	resulted	in	non-synonymous	protein	coding	changes.		
	Figure	24.	Venn	diagram	showing	site	level	evaluation	for	variants	in	the	targeted	pulldown	






In	 addition	 to	 site-level	 comparisons,	 I	 also	 carried	 out	 genotype	 concordance	evaluations	 (Table	 15)	 between	 variants	 in	 the	 pulldown	dataset	 (Illumina	 and	PacBio	pulldown)	 and	 variants	 from	 the	1000	Genomes	dataset	 (Gold	 standard	dataset).	 In	 addition,	 SNPs	 used	 for	 this	 initial	 comparison	 were	 included	regardless	of	whether	they	were	located	in	repetitive	and	non-repetitive	regions.	I	found	moderate	levels	of	sensitivity	and	precision	between	the	pulldown	dataset	and	 1000	 Genomes	 dataset	with	 values	 ranging	 from	 86-92%	 for	 both	metrics	(Table	16).	The	low	specificity	(34-66%)	between	variants	in	the	pulldown	dataset	and	the	1000	Genome	project	suggests	that	the	pulldown	dataset	may	contain	a	high	number	of	calls	which	may	be	false	positives.		
	














Table	16.	Comparison	table	between	PacBio	and	Illumina	enrichment	dataset	and	the	1000	genomes	dataset	for	all	single	nucleotide	variants	in	the	entire	IFITM	locus,	including	repetitive	regions.				 Samples	 	Precision	(%)	 Sensitivity	(%)	 	Specificity	(%)	
PacBio	
HG00478	 88.0	 91.0	 34.9	HG00524	 91.0	 89.0	 48.6	HG00530	 90.0	 88.0	 41.0	HG00533	 89.0	 85.0	 43.5	HG00557	 88.0	 91.0	 35.9	HG01108	 85.0	 84.0	 46.3	NA11994	 90.0	 88.0	 45.2	NA12154	 90.0	 88.0	 52.1	NA12155	 87.0	 83.0	 51.7		 Average	 88.7	 87.4	 44.4	
Illumina	
HG00478	 93.0	 92.0	 48.4	HG00524	 93.0	 92.0	 53.8	HG00530	 92.0	 87.0	 50.0	HG00533	 90.0	 84.0	 53.3	HG00557	 94.0	 87.0	 66.7	HG01108	 91.0	 86.0	 53.7	NA11994	 91.0	 90.0	 38.2	NA12154	 93.0	 90.0	 52.6	NA12155	 92.0	 91.0	 51.3		 Average	 92.1	 88.8	 52.0	
	
















	 Samples	 Precision	(%)	 Sensitivity	(%)	 Specificity	(%)	
PacBio	
HG00478	 96.0	 99.0	 95.0	HG00524	 98.2	 97.0	 98.5	HG00530	 98.1	 96.0	 97.5	HG00533	 98.6	 95.0	 97.0	HG00557	 97.2	 99.0	 96.0	HG01108	 98.0	 97.0	 98.0	NA11994	 98.0	 96.0	 97.0	NA12154	 99.0	 98.0	 96.3	NA12155	 98.0	 98.6	 97.0		 Average	 97.9	 97.3	 96.9	
Illumina	

















HG01108 PacBio sequencing reads
HG01108 Illumina sequencing 
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HG01108 whole-exome sequencing 
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	Figure	28.	Panel	to	represent	the	genotype	calls	for	nine	samples	sequenced	in	the	study.	All	the	genotypes	for	the	eight	SNPs	shown	under	rsID	were	validated	by	Sanger	sequencing.	Sanger	sequencing	 results	were	 therefore	 used	 to	mark	 any	 given	 genotypes	 as	 “correct”	 in	 orange	 or	“incorrect”	 in	 blue.	 Samples	 names	 are	 given	 as	 HG00478,	 HG00524,	 HG00530,	 HG00533,	HG00557,	HG01108,	NA11994,	NA12154,	NA12155	whilst	the	rsID	represents	the	positions	that	were	validated	by	Sanger	sequencing.	Reference	calls	are	represented	as	“0/0”;	heterozygous	calls	are	represented	as	“0/1”	and	homozygous	calls	as	“1/1”.	The	panel	 is	 further	divided	into	three	sections:	PacBio	 IFITM	Pulldown	shows	the	genotypes	of	 the	eight	SNPs	called	using	 the	PacBio	dataset;	 Illumina	 IFITM	 Pulldown	 shows	 the	 genotypes	 of	 these	 same	 eight	 SNPs	 called	 in	 the	Illumina	dataset	and	Phase	3,	1000	Genome	Project	shows	the	genotypes	of	the	same	eight	SNPs	in	the	1000	Genome	Project.	The	PacBio	section	shows	all	the	genotypes	called	using	this	dataset	are	validated	as	correct	by	sanger	sequencing	(all	in	orange).	Genotypes	for	six	SNPs	were	incorrectly	called	across	samples	as	heterozygous	in	the	Illumina	dataset	(positions	in	blue).	Four	SNPs	were	either	incorrectly	called	in	the	1000	Genome	Projects	dataset	(in	blue)	or	not	called	at	all	(shown	in	grey).	
PacBio	IFITM 	Pulldownrs	ID Functional	Consequence Position/Alleles HG00478 HG00524 HG00530 HG00533 HG00557 HG01108 NA11994 NA12154 NA12155rs7479267	 Upstream	of	IFITM3 11	320988	G	A 1/1 0/1 1/1 1/1 1/1 0/0 1/1 1/1 0/1rs71452596Upstream	of	IFITM3 11	320991	G	T 1/1 0/1 1/1 1/1 1/1 0/0 1/1 1/1 0/1rs7478728	 Upstream	of	IFITM3 11	320994	G	A 1/1 0/1 1/1 1/1 1/1 0/0 1/1 1/1 0/1rs6598045 Upstream	of	IFITM3 11	321001	A	G 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0rs3888188 Upstream	of	IFITM3 11	321017	A	C 1/1 0/1 1/1 1/1 1/1 0/0 0/0 0/0 0/0rs28602580	Upstream	of	IFITM3 11	321044	G	A 0/0 0/0 0/0 0/0 0/0 0/0 1/1 0/1 0/1rs35409983	Upstream	of	IFITM3 11	321055	G	T 0/0 0/0 0/0 0/0 0/0 0/0 1/1 0/1 0/1rs35218683Upstream	of	IFITM3 11	321138	C	T 0/1 0/0 0/0 0/0 0/0 0/0 1/1 0/1 0/1
Illumina	IFITM 	Pulldownrs7479267	 Upstream	of	IFITM3 11	320988	G	A 0/1 0/1 0/1 0/1 0/1 0/0 1/1 1/1 0/1rs71452596Upstream	of	IFITM3 11	320991	G	T 0/1 0/1 0/1 0/1 0/1 0/0 1/1 1/1 0/1rs7478728	 Upstream	of	IFITM3 11	320994	G	A 0/1 0/1 0/1 0/1 0/1 0/0 1/1 1/1 0/1rs6598045 Upstream	of	IFITM3 11	321001	A	G 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0rs3888188 Upstream	of	IFITM3 11	321017	A	C 1/1 0/1 1/1 1/1 1/1 0/1 0/0 0/1 0/1rs28602580	Upstream	of	IFITM3 11	321044	G	A 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/1 0/1rs35409983	Upstream	of	IFITM3 11	321055	G	T 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/1 0/1rs35218683Upstream	of	IFITM3 11	321138	C	T 0/1 0/0 0/0 0/1 0/0 0/0 1/1 0/1 0/1
































































4.1.3.2.				Host	genetic	determinants	of	HIV	extreme	phenotypes:	Long	term	non-progressors	and	elite	controllers			 The	natural	control	of	viral	replication	in	the	absence	of	treatment	is	rare	and	 only	 observed	 in	 approximately	 1%	 or	 less	 of	 the	 HIV-infected	individuals(194).	The	mechanisms	by	which	these	patients	are	able	to	control	HIV	replication	 are	 still	 being	 elucidated	 but	 are	 likely	 to	 be	 influenced	 by	 a	combination	of	factors,	including	the	virus	strain,	background	genetic	factors	and	individual	immune	responses(195).	






observed	 in	 greater	 frequency	 in	 Europeans	 and	 North	 American	 elite	 control	cohorts	 whilst	 HLA-B*57:03	 is	 enriched	 in	 elite	 control	 populations	 of	 African	descent(202).			Previous	studies	have	proposed	that	CD4+	T	cells’	resistance	to	infection	explained	the	control	of	viral	populations	observed	in	elite	controllers	and	LTNP.	However,	CD4+	T-cells	from	elite	controllers	support	infection	of	both	T-tropic	and	M-tropic	viruses	 in	 vitro	 to	 comparable	 levels	 to	 CD4+	 T-cells	 from	 HIV-free	individuals(203),	suggesting	that	resistant	CD4+	T-cells	in	elite	controllers	may	not	play	an	important	role	in	the	natural	control	of	these	individuals.		Increased	levels	of	broadly	neutralising	antibodies	have	also	been	suggested	as	a	possible	reason	for	disease	control	in	controllers	but	reports	of	lower	neutralising	antibody	(NAb)	activity	amongst	the	elite	controller	groups	discard	this	hypothesis	and	 suggest	 that	 Nab	may	 not	 play	 a	 major	 role	 in	 the	 natural	 control	 of	 HIV	infection(187).	Other	factors	such	as	CD8+	mediated	control	due	to	secretion	of	IL-2	 and	 IFN-g	 by	 CD8+	 T-cells	 have	 also	 been	 reported	 in	 the	 elite	 control	groups(200).	Similarly,	a	32-base	pair	deletion	 in	the	CCR5	receptor	(CCR5D32)	has	 been	 identified	 to	 confer	 protection	 to	 HIV-1	 viruses	 that	 require	 CCR5	receptor	for	entry	into	the	cell	(HIV1-	R5	tropic	strains)(95,	204).	Taken	together,	all	the	evidence	suggests	that	other	factors	are	also	at	play.	






greater	decrease	in	CD4+	T-cell	counts	and	were	more	likely	to	experience	clinical	adverse	events,	 compared	 to	 the	R5-tropic	 infected	 individuals(206).	Follow	up	studies	of	both	groups	also	found	that	once	patients	had	started	therapy,	the	CD4+	cell	count	and	the	viral	suppression	was	comparable	between	both	groups(206).	In	a	similar	study,	a	US	team	determined	that	the	presence	of	dual/mixed	R5/X4	HIV	 viruses	 also	 increased	 disease	 progression.	 They	 found	 that	 R5/X4	 HIV	infected	patients	 (n=30)	were	 twice	 as	 likely	 to	have	 reduced	CD4+	 cell	 counts	(<350	cell/mm3),	be	initiated	into	antiretroviral	treatment	or	die	compared	to	R5-tropic	 infected	 individuals	 (n=270)(207).	 Although	 follow-up	 information	 was	missing,	it	suggests,	in	line	to	what	was	previously	reported,	that	X4-tropic	viruses	may	speed-up	the	rate	of	HIV	progression	to	AIDS.		




























































































































































































4.3.6.				Identification	of	individuals	with	elevated	missing	rate	or	outlying	heterozygosity		 Before	 embarking	 in	downstream	analysis,	 I	 carried	out	 a	number	of	QC	steps	to	assess	the	quality	of	the	sequencing	data.	These	steps	were	conducted	at	the	individual	and	variant	levels.			







	Figure	36.	Representation	of	heterozygosity	and	missing	rate	 in	 the	HIV	cohort.	The	x	axis	represents	 the	distribution	of	missing	genotypes	 for	each	 individual.	Any	 individuals	with	>	2%	missing	genotype	calls	were	excluded	(vertical	dashed	line).	This	resulted	in	a	total	of	28	samples	excluded	from	downstream	analysis.	The	y-axis	represents	the	distribution	of	the	heterozygosity	rate	for	each	individual.	 Individuals	with	heterozygosity	rate	±	3.5	standard	deviations	from	the	mean	were	also	excluded	from	downstream	analysis.	A	total	of	two	samples	were	excluded	due	to	reduced	heterozygosity.					
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Genome,	 phase	 3	 dataset	 and	 pruned	 markers	 in	 high	 linkage	 disequilibrium	(LD)(225)	 using	 PLINK	 version	 1.9.	 The	 PCA	 calculation	was	 carried	 out	 using	EIGENSTRAT	package(224).	Due	to	the	genetic	differences	across	populations	in	the	1000	Genome	dataset,	only	two	principal	components	were	sufficient	to	cluster	individuals	 in	 the	 exome	 dataset	 alongside	 individuals	 from	 1000	 Genomes	dataset.	The	results	from	the	PCA	analysis	demonstrated	that	a	total	of	66	samples	were	not	of	European	descent	and	should	be	excluded	from	downstream	analysis	(Figure	38).		
	Figure	38.	Principal	component	analysis	(PCA)	of	whole	exome	HIV	sequencing	data.		Principal	component	 clustering	 was	 built	 using	 2,504	 individuals	 from	 African,	 South	 Asian,	 East	 Asian,	American,	 Finish	 and	 European	 populations	 from	 1000	 Genomes	 phase	 3	 dataset.	 These	populations	were	used	to	predict	the	ancestry	of	the	240	samples	(of	supposed	European	ancestry)	from	HIV	whole	exome	dataset.	A	total	of	68	samples	clustered	away	from	the	European	samples	and	were	excluded	from	the	study.	The	circle	surrounding	the	black	dots	represent	the	172	HIV	whole	exome	samples	 that	 clustered	with	European	 samples	and	 thus,	 included	 in	downstream	analysis.				Furthermore,	I	identified	4	samples	with	identity	by	state	(IBD)	score	>	0.185,	a	value	which	is	suggestive	of	relatedness	or	duplication	between	individuals(132).	Any	standard	population-based	study	require	that	all	the	samples	are	unrelated.	In	






























































		4.4.1.2.				Replicating	the	association	for	IFITM3	SNP	rs12252		 In	a	genetic	association	study	of	HIV-1	infection	prognosis	consisting	of	74	rapid	 progressors	 and	 104	 elite	 controllers,	 Zhang	 and	 colleagues	 reported	 an	association	 for	 SNP	 rs12252	 (P	 =	 0.002,	 OR	 =	 3.778	 (95CI-	 1.5–9.7)	 under	 a	dominant	model.	They	found	that	92%	of	rapid	progressors	(68/74)	carried	the	CC/CT	genotypes,	compared	to	75%	of	non-progressors	(78/108)(88).			In	my	study,	I	was	unable	to	replicate	this	finding.	In	fact,	I	found	that	the	direction	of	effect	for	the	C	allele	is	in	the	opposite	direction	to	what	is	reported	in	their	study	(OR	=	0.64	(95CI	-	0.12-3.25,	additive	model)	(Table	19).	Although,	I	carried	out	the	analysis	under	different	models:	Cochran-Armitage	trend	test,	a	1df	allelic	test,	a	dominant	model	(for	the	minor	allele)	test	and	a	recessive	model	(for	the	minor	
Genes	 rs	ID	 AF	cases	
AF	










allele),	 I	 was	 unable	 to	 obtain	 significant	 evidence	 of	 replication	 under	 the	dominant	or	recessive	models.	One	potential	reason	for	the	lack	of	replication	is	the	 low	 frequency	 of	 this	 risk	 allele	 (give	 the	 frequency	 and	 the	 allele	 in	 your	cohort)	in	the	cohort	analysed	in	this	study,	compared	to	the	PRIMO	cohort(88).	Of	course,	another	potential	reason	for	the	lack	of	replication	could	be	that	the	initial	association	is	a	false-positive	finding.		Table	19.	Table	of	association	tests	for	SNP	rs12252.	The	top	row	“This	study”	shows	the	association	summary	statistics	in	my	analysis.	The	values	for	Zhang	et	al,	are	shown	underneath.	
P-values	are	uncorrected	for	multiple	testing	but	do	not	reach	genome-wide	significance	(5x10-8)	
Study	 ID	 Cases	 Control	 P	 OR	(95%	CI)	 AF	 EAS	AF	
EUR	
AF	
This	study	 rs12252	 0.02	 0.28	 0.59	 0.64	(0.12-3.25)	 0.24	 0.53	 0.04	Zhang	et	























ATHL1	 5	 3	 All	missense	variants	 0.93	 0.83	
IFITMs	(1,2,3)	 4	 3	 All	missense	variants	 0.8	 1	
B4GALNT4	 7	 11	 All	missense	variants	 0.12	 1		 	 	 	 	 	
ATHL1	 5	 3	 Rare	missense	variants		(1KP)	 0.93	 0.83	
IFITMs	(1,2,3)	 1	 1	 Rare	missense	variants		(1KP)	 1	 1	
B4GALNT4	 7	 11	 Rare	missense	variants		(1KP)	 0.12	 1		 	 	 	 	 	


















pathogenic	 loss	 of	 function	 and	 missense	 variants	 were	 present	 in	 ~11%	 of	intellectual	disability	cases	from	a	cohort	of	986	individuals	(113	variants	in	107	individuals)(145).	Using	a	much	 larger	 cohort	of	 individuals	of	4,264	 cases	 and	9,343	 controls,	 Singh	 and	 colleagues	 detected	 an	 enrichment	 of	 rare	 loss	 of	function	 variants	 in	 SET	 Domain	 Containing	 1A	 (SETD1A)	 gene	 that	 encodes	 a	protein	 from	 a	 histone	 methyltransferase	 (HMT)	 complex(141).	 Although	 the	number	 of	 samples	 in	 each	 individual	 cohort	 varied	 and	 functional	 follow-up	studies	will	be	necessary,	it	appears	that	the	contribution	of	some	loss	of	function	and	 missense	 rare	 variants	 to	 the	 risk	 of	 disease	 such	 as	 heart	 conditions,	intellectual	disability	or	schizophrenia,	is	considerable.	It	is	possible	that	the	same	approach	could	be	used	in	future	experimental	designs	to	study	HIV.		The	 design	 of	 a	 comprehensive	 analysis	 of	 host	 factor	 contribution	 to	 HIV-1	progression	 is	 still	 of	 paramount	 importance	 and	 future	 studies	 could	 also	investigate	 other	 forms	 of	 variation	 such	 as	 copy	 number	 variation(128).	Differences	in	copy	number	variants	have	been	shown	to	be	important	for	HIV-1	disease	 progression	 within	 specific	 populations.	 For	 example,	 if	 an	 individual	carries	 copy	number	of	C-C	Motif	Chemokine	3-Like	1	 (CCL3L1)	 lower	 than	 the	average	 copy	 number	 observed	 for	 the	 general	 population	 from	 which	 that	individual	originates,	he/she	will	be	more	susceptible	to	HIV-1	infection(128).	It	is	believed	that	increased	doses	of	CCL3L1	could	affect	HIV-1	in	a	number	of	ways:	by	inhibiting	the	binding	of	gp120	to	the	CCR5	co-receptor,	inducing	CCR5	co-receptor	internalisation,	 leading	 to	 a	 decrease	 in	 the	 receptors	 on	 cell	 membranes	 or	influencing	leukocyte	trafficking	involved	in	virus	restriction(128).	
	4.5.2.			Future	candidate	gene	studies	for	IFITM	
















































































































































































































































































































5.3.1.2.4.				Variant	Annotation		 Following	variant	calling	and	QC,	I	annotated	variants	using	dbSNP	v137.	I	used	 Ensembl	 Variant	 Effect	 predictor	 (Ensembl	 variation	 release	 76)	 for	annotation	and	used	the	most	severe	predicted	consequence	for	each	gene	variant.	I	 used	 Scoring	 Intolerance	 from	 Tolerance	 (SIFT)(220)	 and	 Polyphen-2(221)	predictions	 to	 determine	 whether	 the	 variants	 were	 likely	 to	 affect	 protein	function,	and	the	Sequence	Ontology	terms	and	description	 in	Ensembl	 to	score	variants	for	their	functional	impact	on	the	function	of	the	protein		5.3.1.2.5.				Identification	of	Individuals	with	elevated	missing	genotype	rate	or	outlying	heterozygosity	
	 I	followed	the	data	quality	in	case-control	association	studies	by	Anderson,	






	Figure	 42.	 Identification	 of	 individuals	 with	 high	 missing	 genotype	 and	 outlying	































































































































	Figure	43.	Histogram	of	the	number	of	variants	with	missing	genotype	data.	The	dashed	vertical	line	represents	the	QC	threshold	(13%)	used	to	filter	out	SNPs	with	high	missing	rate.	In	total,	28	SNPs	were	removed	out	of	909	SNPs.					5.3.1.2.6.				Phasing	the	Vietnamese	sequencing	data	using	SHAPEIT2	 	In	order	to	construct	the	reference	panel,	I	proceeded	to	phase	the	QC’ed	sequencing	data	using	SHAPEIT2(249),(250).	There	are	three	phasing	strategies	currently	 listed	by	 SHAPEIT2.	Because,	 it	was	unknown	which	 specific	 strategy	would	work	best	on	my	data,	I	phased	with	all	the	three	methods	and	evaluated	according	to	switch	errors	and	Info	metrics.	In	the	following	section,	I	give	more	details	on	the	different	phasing	strategies	that	I	employed:		phasing	with	 a	 reference	 panel	 scaffold,	 phasing	without	 a	 reference	 and	 Read	Aware	 Phasing	 (PIRS).	 I	 then	 proceeded	 to	 evaluate	 the	 phasing	 output	 by	comparing	the	switch	error	rate	and	the	flip	errors	between	outputs.		1. Phasing	the	Vietnamese	samples	using	1000	Genomes	Phase	3	Reference	Panel	as	scaffold	I	 first	 downloaded	 1000	 Genomes	 Reference	 panel	 from	https://mathgen.stats.ox.ac.uk/impute/1000GP_Phase3.html	 and	proceeded	 to	 compare	variants	 called	 in	my	dataset	with	variants	 in	 the	























samples,	 I	 carried	 out	 several	 combinations	 of	 comparisons	 between	 phased	haplotypes	 from	 all	 three	 phased	 panels.	 I	 found	 that	 phasing	 with	 the	 1000	Genomes	as	a	scaffold	resulted	in	1,127	error	rates;	without	a	scaffold,	1,066	and	with	PIRs,	575.	The	results	were	similar	but	suggested	that	PIRS	contained	the	least	number	of	switch	error	rates.	This	is	consistent	with	previous	findings	that	found	using	PIRS	in	real	data	from	1000	Genomes	dataset	would	reduce	the	switch	error	rate	substantially(251)	



































5.4.3.				Power	to	detect	associations		Following	QC	 of	 SNPs	 in	 the	 severe	 dengue	 dataset,	 18	 directly	 genotyped	 and	1,817	imputed	SNPs	of	MAF	³1%	were	available	for	GWAS	across	the	IFITM	region	(chr11:280,000-380,000).	With	2,008	cases	of	Vietnamese	children	with	dengue	shock	syndrome	and	2,018	controls	cord	blood	controls	and	using	a	genome-wide	significance	threshold	of	P	values	<5x10-8,	 this	study	had	>90%	power	to	detect	common	variants	with	allele	 frequencies	of	at	 least	5%	and	moderate	and	 large	effect	sizes	(OR³2.0)	(Figure	46).	For	low-frequency	variants	of	1%,	80%	power	was	only	achieved	for	large	effect	sizes	(OR³3)	(Figure	46).			















alternate_ids rsidchromosome position alleleA alleleB all	maf cases	maf controls	maf OR OR	lower OR_upper P	value
11 rs760060 11 288883 A G 0.13 0.11 0.14 0.81 0.71 0.93 0.0025
11 rs10902119 11 288115 T C 0.12 0.11 0.13 0.82 0.72 0.94 0.0043
11 rs61876261 11 356080 T C 0.14 0.16 0.13 1.20 1.06 1.36 0.0043
11 rs186373656 11 302039 C T 0.20 0.21 0.19 1.18 1.05 1.31 0.0048
11 rs11246052 11 286134 G A 0.10 0.09 0.11 0.82 0.71 0.94 0.0057
11 rs11246117 11 353630 G A 0.26 0.24 0.27 0.87 0.79 0.96 0.0065
11 rs11600194 11 287959 G A 0.10 0.10 0.11 0.82 0.71 0.95 0.0073
11 rs78642272 11 351271 G A 0.17 0.16 0.18 0.86 0.76 0.97 0.0090
11 rs183397121 11 334170 C G 0.12 0.13 0.12 1.20 1.05 1.36 0.0094
11 rs3932433 11 289553 G C 0.10 0.09 0.11 0.83 0.72 0.96 0.0107
11 rs3809112 11 307036 T C 0.31 0.30 0.33 1.13 1.03 1.24 0.0109
11 rs10902121 11 306791 T C 0.31 0.30 0.33 1.13 1.03 1.24 0.0126
11 rs117779161 11 343820 G A 0.14 0.13 0.14 0.85 0.75 0.97 0.0129
11 rs11246099 11 347878 T A 0.17 0.16 0.18 1.16 1.03 1.30 0.0139
11 rs11246059 11 305961 A C 0.49 0.50 0.47 1.12 1.02 1.22 0.0145
11 rs7948108 11 323507 G A 0.31 0.30 0.33 0.89 0.81 0.98 0.0147
11 rs11246062 11 313755 C G 0.45 0.43 0.46 1.12 1.02 1.22 0.0157
11 11:308178 11 308178 T C 0.37 0.36 0.38 1.12 1.02 1.22 0.0171
11 rs10398 11 308180 A G 0.39 0.38 0.40 1.11 1.02 1.22 0.0188







The design of this study with 2,008 cases and 2,018 controls, using a genome-wide 
threshold of P < 5x10-8, had 100% power to detect common variants with minor allele 
frequencies of at least 30% with effect sizes (OR > 2.0) (Figure 46). However, despite 






a	 reliance	 on	 simple	 tourniquet	 tests	 (approved	 by	 the	 WHO	 to	 test	 capillary	fragility)	for	diagnosis	of	dengue	haemorrhagic	fever.	It	has	been	reported	that	this	test	differentiates	badly	between	dengue	haemorrhagic	fever	(45%	positive)	and	dengue	 fever	 (38%	positive)(254).	 Probably	 the	 best	 study	 yet	 to	 highlight	 the	challenges	of	good	study	design	for	dengue	disease	was	undertaken	Anders	KL,	et.	


















this	report	was	published.	I	found	that	both	methods	captured	most	of	the	variation	in	 the	 target	 region.	 Although	 PacBio	 sequencing	 marginally	 outperformed	Illumina	sequencing	in	‘difficult’	regions	near	the	IFITM3,	the	high	cost	of	reagents	and	manual	 effort	 involved	 in	 adapting	 the	 technology	 to	work	with	PacBio	RS,	guided	 the	 decision	 to	 employ	 Illumina	 in	 future	 IFITM	 targeted	 sequencing	studies.			In	Chapter	4,	I	applied	the	conventional	targeted	sequencing	method	described	in	Chapter	3	to	test	genetic	variants	 in	and	around	 IFITM1,	 IFITM2	and	 IFITM3	 for	association	with	the	rapid	disease	progression	in	HIV.	I	also	explored	the	burden	of	 low-frequency	 and	 rare	 genetic	 variants	 (MAF	 <	 5%)	 to	 this	 phenotype	 by	testing	 for	 a	 differential	 enrichment	 between	 HIV	 elite	 controllers	 and	 rapid	progressors	across	each	of	the	three	genes.	Because	of	the	limited	sample	size	in	this	study,	I	also	decided	to	analyse	other	larger	cohorts	of	infectious	disease	cases	and	controls	to	test	for	significant	associations	to	the	IFITM	genes.	In	Chapter	5,	I	described	 the	 association	 analysis	 in	 a	 cohort	 of	 2,008	 Vietnamese	 children	diagnosed	with	dengue	haemorrhagic	fever	(DHF)	and	2,018	cord	blood	controls.	To	 increase	 the	number	of	variants	 to	 test	 for	association,	 I	also	constructed	an	


















coverage	 of	 variants	 present	 in	 these	 non-European	 populations	 in	 most	genotyping	chips.	This	historical	population	bias	in	genotyping	arrays	is	changing	and	 there	 are	 currently	 several	 genotyping	 arrays	 available	 to	 the	 scientific	community	that	capture	variation	in	non-European	populations	(258).			The	coverage	is	further	reduced	following	typical	quality	control	steps	in	genome-wide	association	studies.	For	example,	in	a	study	of	Primary	Sclerosing	Cholangitis	(PSC)	in	2014,	Liu	and	colleagues	genotyped	3,789	PSC	cases	of	European	ancestry	and	25,079	population	controls	using	the	Immunochip.	Close	examination	of	their	quality	 control	 steps	 revealed	 that	 approximately	 61,000	 variants	 (out	 of	~196,000)	 included	 in	 the	 array,	 did	 not	 pass	 the	 quality	 control	 assessments	generally	 employed	 in	 these	 studies.	 Similarly,	 Kumar	 and	 colleagues,	 obtained	only	118,989	(out	of	~196,000)	SNPs	from	the	217	candidaemia	cases	and	11,920	healthy	controls	after	applying	standard	quality	parameters(259).	There	will	be	a	number	of	 factors	 that	will	 contribute	 to	 the	 failure	of	 a	particular	 SNP	 to	pass	quality	controls.	 It	 is	 certainly	 the	case	 that	although	quality	control	 steps	have	been	standardised	for	genome	wide	association	studies,	each	centre	will	employ	specific	threshold	that	are	more	appropriate	for	their	data.	Importantly,	many	of	the	variants	included	in	arrays	are	selected	from	publicly	available	datasets	such	as	the	1000	Genomes.	In	Chapter	3,	I	provided	a	snapshot	of	the	problem	when	I	showed	that	for	a	600bp	region	at	the	5’	end	of	the	IFITM3,	all	non-reference	calls	for	 8	 sampled	 SNPs	 were	 incorrectly	 called	 in	 that	 dataset.	 Although	 similar	situations	 in	 the	 rest	 of	 the	 genome	 may	 be	 rare,	 when	 they	 happen,	 it	 could	negatively	impact	the	discovery	of	new	associations.		












a	study	of	major	depressive	disorder	(MDD)	in	22,158	cases	and	133,749	controls	identified	only	one	significant	association:	rs7647854	(p	=	5.2	×	10-11)(264).	The	study	of	MDD	has	been	challenging	due	to	a	moderate	heritability	(20%)	and	the	heterogeneity	 of	 the	 genetic	 factors	 that	 contribute	 to	 the	 condition(265).	Although	we	hope	that	infectious	diseases	will	not	be	as	challenging	for	GWAS	as	MDD	 is,	 what	 these	 studies	 suggest	 is	 that	 other	 approaches	 will	 be	 needed	alongside	genome-wide	studies	to	understand	the	genetic	architecture	of	disease.		



















	Figure	47.	Artemis	 coverage	and	 stack	view	of	 the	 IFITM	 locus	 in	DF1	 cells	 following	pull	
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